Figure 2.
Metastatic castration‐resistant prostate cancer (mCRPC) usage proportion for LOT1 by age group. (A) individual year commercial claims cohorts from 2010 to 2013a; (B) 2013 commercial claims and EMR cohorts. EMR, electronic medical record; LOT1, first line of treatment. amCRPC drug usage proportion in each of the age groups (44–64, 65–80, >80 years) was significantly different (P < 0.0001) for each of these agents comparing years 2010–2013.